syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-pet and radioimmunotherapy. a preclinical study on mda-mb-468 xenograft tumorssyndecan-1抗原,一种很有前途的新目标三阴性乳腺癌immuno-pet和放射。.pdfVIP

下载本文档

0
0
约6.67万字
约 11页
2017-09-12 发布于上海
举报
版权申诉

syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-pet and radioimmunotherapy. a preclinical study on mda-mb-468 xenograft tumorssyndecan-1抗原,一种很有前途的新目标三阴性乳腺癌immuno-pet和放射。.pdf

1、本文档共11页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-pet and radioimmunotherapy. a preclinical study on mda-mb-468 xenograft tumorssyndecan-1抗原,一种很有前途的新目标三阴性乳腺癌immuno-pet和放射。

Rousseau et al. EJNMMI Research 2011, 1:20 /content/1/1/20 ORIGINAL RESEARCH Open Access Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors 1,2† 2† 2 1,2,3 2 Caroline Rousseau , Anne Lise Ruellan , Karine Bernardeau , Françoise Kraeber-Bodéré , Sebastien Gouard , 4 2 2 5 2 Delphine Loussouarn , Catherine Saï-Maurel , Alain Faivre-Chauvet , John Wijdenes , Jacques Barbet , Joëlle Gaschet2, Michel Chérel1,2 and François Davodeau2* Abstract Background: Overexpression of syndecan-1 (CD138) in breast carcinoma correlates with a poor prognosis and an aggressive phenotype. The objective of this study was to evaluate the potential of targeting CD138 by immuno- PET imaging and radioimmunotherapy (RIT) using the antihuman syndecan-1 B-B4 mAb radiolabeled with either 124I or 131I in nude mice engrafted with the triple-negative MDA-MB-468 breast cancer cell line. Method: The immunoreactivity of 125I-B-B4 (80%) was determined, and the affinity of 125I-B-B4 and the expression of CD138 on MDA-MB-468 was measured in vitro by Scatchard analysis. CD138 expression on established tumors was confirmed by immunohistochemistry. A biodistribution study was performed in mice with subcutaneous MDA- MB-468 and 125I-B-B4 at 4, 24, 48, 72, and 96 h after injection and compared with an isotype-matched control. Tumor uptake of B-B4 was evaluated in vivo by immuno-PET imaging using the 124I-B-B4 mAb. The maximum tolerated dose (MTD) was determined from mice treated with 131I-B-B4 a